Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...

That “waste-to-value” is increasingly getting quiet attention from private equity and infrastructure investors.

Trump opened the door for private equity to tap 401(k)s, and now private equity bosses want legal protection. Here's what ...

Wall Street is often blamed for reducing corporate managers’ understanding of business to a single, gameable measure of ...

In 2025’s go-go leveraged debt markets, everything is up for negotiation, but a trio of investor protections are proving to ...

Private-equity executives entered 2025 with high hopes for a dealmaking recovery that is lifting payouts to fund investors and powering fundraising.

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Successful firms are increasingly split between behemoths with several business lines and those focusing on their roots of ...

As private equity continues to shape the Irish M&A landscape, experts predict strong activity in the coming years, fueled by ...

In 2024, global private equity and venture capital transaction value and volume in biotechnology declined to their lowest ...

Last month, a deal for Sycamore Partners to buy pharmacy chain Walgreens was seen as “mostly dead,” but reports say it may ...

Health Affairs' Jeff Byers welcomes Senior Editor Kathleen Haddad back to the program to discuss two recent reports exploring the impacts of private equity on the US health care system.